CN220846152U - Device for producing D-chiral inositol and glucuronic acid by utilizing inositol - Google Patents
Device for producing D-chiral inositol and glucuronic acid by utilizing inositol Download PDFInfo
- Publication number
- CN220846152U CN220846152U CN202322508203.9U CN202322508203U CN220846152U CN 220846152 U CN220846152 U CN 220846152U CN 202322508203 U CN202322508203 U CN 202322508203U CN 220846152 U CN220846152 U CN 220846152U
- Authority
- CN
- China
- Prior art keywords
- inositol
- communicated
- pipeline
- glucuronic acid
- outlet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 title claims abstract description 88
- 229960000367 inositol Drugs 0.000 title claims abstract description 64
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 title claims abstract description 62
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 title claims abstract description 62
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 title claims abstract description 44
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 229940097043 glucuronic acid Drugs 0.000 title claims abstract description 44
- 239000012528 membrane Substances 0.000 claims abstract description 63
- 239000000243 solution Substances 0.000 claims abstract description 50
- 239000003957 anion exchange resin Substances 0.000 claims abstract description 45
- 239000000919 ceramic Substances 0.000 claims abstract description 33
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- 239000007788 liquid Substances 0.000 claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000000108 ultra-filtration Methods 0.000 claims description 30
- CDAISMWEOUEBRE-LKPKBOIGSA-N 1D-chiro-inositol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-LKPKBOIGSA-N 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 11
- 239000003729 cation exchange resin Substances 0.000 claims description 11
- 238000000967 suction filtration Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 6
- 238000011010 flushing procedure Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000047 product Substances 0.000 abstract description 9
- 238000000926 separation method Methods 0.000 abstract description 8
- 239000011259 mixed solution Substances 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 3
- 239000006227 byproduct Substances 0.000 abstract description 3
- 239000000843 powder Substances 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 208000028659 discharge Diseases 0.000 description 2
- 239000012527 feed solution Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The utility model discloses a device for producing D-chiral inositol and glucuronic acid by utilizing inositol, which relates to the technical field of pharmacy, wherein an inositol solution reacts in a first conversion kettle to obtain a mixed solution of the D-chiral inositol and the inositol, then the mixed solution enters a second conversion kettle after passing through a ceramic membrane device and is converted into the glucuronic acid, the glucuronic acid enters an anion exchange resin column for glucuronic acid adsorption, the D-chiral inositol enters a first concentrator as effluent liquid, ethanol is added, and then the D-chiral inositol is concentrated, cooled and crystallized to obtain a D-chiral inositol product; and (3) resolving the glucuronic acid, then feeding the glucuronic acid into a second concentrator, concentrating, and finally obtaining the glucuronic acid dry powder through spray drying. By converting unreacted inositol into glucuronic acid and then adsorbing the glucuronic acid by an anion exchange resin column, the separation of D-chiral inositol is realized, the separation cost is saved, the purity of D-chiral inositol is improved, and in addition, the byproduct glucuronic acid improves the economic benefit of enterprises.
Description
Technical Field
The utility model relates to the technical field of pharmacy, in particular to a device for producing D-chiral inositol and glucuronic acid by utilizing inositol.
Background
D-chiro-inositol (DCI) is one of the nine isomers of inositol that has optical activity. In recent years, research has found that D-chiro-inositol (DCI) has not only the function of promoting liver lipid metabolism, but also the special physiological functions of insulin sensitization, blood sugar reduction, improvement of ovulation condition of polycystic ovary syndrome (PCOS) patients, hormone balance adjustment, menstrual disorder improvement, antioxidation, anti-aging and anti-inflammatory.
The chiral inositol is synthesized by a chemical synthesis method, breakthrough is not realized at present, the process steps are complex, and the cost is high. The method for producing D-chiro-inositol by genetic engineering is to convert myo-inositol into D-chiro-inositol by using the genetic modification of bacillus subtilis, and has low bioconversion rate, high cost, and meanwhile, the obtained D-chiro-inositol and myo-inositol are difficult to separate, and the purity of the obtained D-chiro-inositol is low.
Disclosure of Invention
The technical problems to be solved by the utility model are as follows: aiming at the defects existing in the prior art, the device for producing the D-chiral inositol and the glucuronic acid by using the inositol is provided, and the obtained D-chiral inositol has high purity and low reaction cost.
In order to solve the technical problems, the technical scheme of the utility model is as follows:
The device for producing D-chiral inositol and glucuronic acid by utilizing inositol comprises a first conversion kettle, wherein an inlet of the first conversion kettle is respectively communicated with an inositol solution tank, a first enzyme solution tank and a buffer solution tank through pipelines, an outlet of the first conversion kettle is communicated with a ceramic membrane device through a pipeline, a clear solution outlet of the ceramic membrane device is communicated with a second conversion kettle through a pipeline, and an inlet of the second conversion kettle is communicated with a second enzyme solution tank through a pipeline; the outlet of the second conversion kettle is communicated with a filter through a pipeline, and the filtrate outlet of the filter is communicated with an anion exchange resin column through a pipeline;
the outlet of the lower effluent of the anion exchange resin column is communicated with a first concentrator through a pipeline, the inlet of the first concentrator is communicated with an ethanol tank through a pipeline, the outlet of the first concentrator is communicated with a first suction filtration tank through a pipeline, and the outlet of the first suction filtration tank is communicated with a D-chiral inositol tank through a pipeline;
The inlet of the anion exchange resin column is communicated with a hydrochloric acid solution tank through a pipeline, the outlet of the anion exchange resin column is communicated with a second concentrator through a pipeline, the outlet of the second concentrator is communicated with a dryer, and the outlet of the dryer is communicated with a glucuronic acid tank through a pipeline.
As an improved technical scheme, a filtrate outlet of the filter is communicated with an ultrafiltration membrane device through a pipeline, and a clear liquid outlet of the ultrafiltration membrane device is communicated to the anion exchange resin column through a pipeline.
As an improved technical scheme, a concentrated solution outlet of the ceramic membrane device is communicated with a ceramic membrane concentrated solution tank through a pipeline, and a concentrated solution outlet of the ultrafiltration membrane device is communicated with an ultrafiltration membrane concentrated solution tank through a pipeline.
As an improved technical scheme, a clear liquid outlet of the ultrafiltration membrane device is communicated with a cation exchange resin column through a pipeline, and an outlet of the cation exchange resin column is communicated with an anion exchange resin column through a pipeline.
As an improved technical scheme, the aperture of the ultrafiltration membrane device is 1000-10000Da.
As an improved technical scheme, the pore diameter of the ceramic membrane device is 20-100nm.
As a preferable technical scheme, the filter is one of a ceramic membrane filter, a centrifugal machine or a plate-frame filter.
As a preferable technical scheme, the lower inlet of the anion exchange resin column is communicated with a flushing water tank through a pipeline, and the upper outlet of the anion exchange resin column is communicated with the first concentrator through a pipeline.
Due to the adoption of the technical scheme, the utility model has the beneficial effects that:
The utility model relates to a device for producing D-chiral inositol and glucuronic acid by utilizing inositol, which comprises a first conversion kettle, wherein an inlet of the first conversion kettle is communicated with an inositol solution tank, a first enzyme solution tank and a buffer solution tank through pipelines respectively, an outlet of the first conversion kettle is communicated with a ceramic membrane device through a pipeline, a clear solution outlet of the ceramic membrane device is communicated with a second conversion kettle through a pipeline, and an inlet of the second conversion kettle is communicated with a second enzyme solution tank through a pipeline; the outlet of the second conversion kettle is communicated with a filter through a pipeline, and the filtrate outlet of the filter is communicated with an anion exchange resin column through a pipeline; the outlet of the lower effluent of the anion exchange resin column is communicated with a first concentrator through a pipeline, the inlet of the first concentrator is communicated with an ethanol tank through a pipeline, the outlet of the first concentrator is communicated with a first suction filtration tank through a pipeline, and the outlet of the first suction filtration tank is communicated with a D-chiral inositol tank through a pipeline; the inlet of the anion exchange resin column is communicated with a hydrochloric acid solution tank through a pipeline, the outlet of the anion exchange resin column is communicated with a second concentrator through a pipeline, the outlet of the second concentrator is communicated with a dryer, and the outlet of the dryer is communicated with a glucuronic acid tank through a pipeline. Reacting the inositol solution with inositol dehydrogenase and inositol monoketone isomerase in a first enzyme liquid tank in a first conversion kettle, regulating the pH value of a buffer solution to 6-7 to obtain a mixed solution of D-chiral inositol and inositol, removing insoluble impurities in the feed liquid by a ceramic membrane device, allowing a ceramic membrane clear solution to enter a second conversion kettle, reacting with a whole-cell catalyst containing inositol oxidase in the second enzyme liquid tank, converting inositol in the mixed solution into glucuronic acid, removing insoluble impurities in the feed liquid by a filter, allowing the mixture to enter an anion exchange resin column, adsorbing the glucuronic acid, allowing the D-chiral inositol as an effluent to enter a first concentrator, adding ethanol, concentrating, cooling for crystallization, and separating by a first suction filtration tank to obtain a D-chiral inositol product; and the glucuronic acid on the anion exchange resin column is resolved by hydrochloric acid solution, the resolved solution enters a second concentrator, and the concentrated and crystallized solution is dried by a dryer to finally obtain the glucuronic acid. By converting unreacted inositol into glucuronic acid and then adsorbing the glucuronic acid by an anion exchange resin column, the separation of D-chiral inositol is realized, the separation cost is saved, the purity of D-chiral inositol is improved, and in addition, the byproduct glucuronic acid improves the economic benefit of enterprises.
The filtrate outlet of the filter is communicated with an ultrafiltration membrane device through a pipeline, and the clear liquid outlet of the ultrafiltration membrane device is communicated with the anion exchange resin column through a pipeline. Macromolecular organic matters and part of macromolecular impurities can be removed through the ultrafiltration membrane, so that the purity of the product is further improved.
The aperture of the ultrafiltration membrane device is 1000-10000Da, the aperture of the ceramic membrane device is 20-100nm, the concentrated solution outlet of the ceramic membrane device is communicated with a ceramic membrane concentrated solution tank through a pipeline, and the concentrated solution outlet of the ultrafiltration membrane device is communicated with an ultrafiltration membrane concentrated solution tank through a pipeline. The liquid in the ceramic membrane concentrate tank and the ultrafiltration membrane concentrate tank is subjected to environment-friendly pollution discharge treatment, and the amount of the generated waste liquid is small and the environment is protected.
The clear liquid outlet of the ultrafiltration membrane device is communicated with a cation exchange resin column through a pipeline, and the outlet of the cation exchange resin column is communicated to the anion exchange resin column through a pipeline. The feed liquid is desalted by a cation exchange resin column, so that the purity of the product is further improved.
The filter is one of a ceramic membrane filter, a centrifugal machine or a plate-frame filter, has good separation effect, improves the purity of the final product, plays a role in concentrating feed liquid, saves the subsequent concentration time, and shortens the process period.
The lower inlet of the anion exchange resin column is communicated with a flushing water tank through a pipeline, and the upper outlet of the anion exchange resin column is communicated to the first concentrator through a pipeline. The anion exchange resin column is washed, so that the material liquid stained on the anion exchange resin column is recovered, waste is avoided, and the utilization rate of raw materials and the yield of products are improved.
Drawings
The utility model will be further described with reference to the drawings and examples.
FIG. 1 is a schematic diagram of an embodiment of the present utility model;
Wherein: 1. a first conversion kettle; 2. an inositol solution tank; 3. a first enzyme solution tank; 4. a buffer tank; 5. a ceramic membrane device; 6. a second conversion kettle; 7. a second enzyme solution tank; 8. a filter; 9. an anion exchange resin column; 10. a first concentrator; 11. an ethanol tank; 12. a first suction canister; 13. d-chiro-inositol tank; 14. a hydrochloric acid solution tank; 15. a second concentrator; 16. a dryer; 17. a glucuronic acid tank; 18. an ultrafiltration membrane device; 19. ceramic membrane concentrate tank; 20. an ultrafiltration membrane concentrate tank; 21. a cation exchange resin column; 22. and (5) flushing the water tank.
Detailed Description
The utility model is further illustrated in the following, in conjunction with the accompanying drawings and examples.
As shown in fig. 1, the device for producing D-chiral inositol and glucuronic acid by using inositol comprises a first conversion kettle 1, wherein an inlet of the first conversion kettle 1 is respectively communicated with an inositol solution tank 2, a first enzyme solution tank 3 and a buffer solution tank 4 through pipelines, an outlet of the first conversion kettle 1 is communicated with a ceramic membrane device 5 through a pipeline, a clear solution outlet of the ceramic membrane device 5 is communicated with a second conversion kettle 6 through a pipeline, and an inlet of the second conversion kettle 6 is communicated with a second enzyme solution tank 7 through a pipeline; the outlet of the second conversion kettle 6 is communicated with a filter 8 through a pipeline, and the filtrate outlet of the filter 8 is communicated with an anion exchange resin column 9 through a pipeline; the lower effluent outlet of the anion exchange resin column 9 is communicated with a first concentrator 10 through a pipeline, the inlet of the first concentrator 10 is communicated with an ethanol tank 11 through a pipeline, the outlet of the first concentrator 10 is communicated with a first suction filtration tank 12 through a pipeline, and the outlet of the first suction filtration tank 12 is communicated with a D-chiro-inositol tank 13 through a pipeline; the inlet of the anion exchange resin column 9 is communicated with a hydrochloric acid solution tank 14 through a pipeline, the outlet of the anion exchange resin column 9 is communicated with a second concentrator 15 through a pipeline, the outlet of the second concentrator 15 is communicated with a dryer 16, and the outlet of the dryer 16 is communicated with a glucuronic acid tank 17 through a pipeline. Reacting inositol solution with inositol dehydrogenase and inositol monoketone isomerase in a first enzyme liquid tank 3 in a first conversion kettle 1, regulating pH to 6-7 with buffer solution to obtain mixed solution of D-chiral inositol and inositol, removing insoluble impurities in the mixed solution through a ceramic membrane device 5, allowing a ceramic membrane clear solution to enter a second conversion kettle 6, reacting with a whole cell catalyst containing inositol oxidase in a second enzyme liquid tank 7 to convert inositol in the mixed solution into glucuronic acid, removing insoluble impurities in the feed solution through a filter 8 again, allowing the mixture to enter an anion exchange resin column 9, adsorbing the glucuronic acid, allowing the D-chiral inositol as effluent to enter a first concentrator 10, adding ethanol, concentrating, cooling for crystallization, and separating through a first suction filtration tank 12 to obtain a D-chiral inositol product; the glucuronic acid on the anion exchange resin column 9 is resolved by hydrochloric acid solution, the resolved solution enters a second concentrator 15, and the concentrated and crystallized solution is dried by a dryer 16 to finally obtain the glucuronic acid. By converting unreacted inositol into glucuronic acid and then adsorbing the glucuronic acid by the anion exchange resin column 9, the separation of D-chiral inositol is realized, the separation cost is saved, the purity of D-chiral inositol is improved, and in addition, the byproduct glucuronic acid improves the economic benefit of enterprises.
The filtrate outlet of the filter 8 is communicated with an ultrafiltration membrane device 18 through a pipeline, and the clear liquid outlet of the ultrafiltration membrane device 18 is communicated with the anion exchange resin column 9 through a pipeline. Macromolecular organic matters and part of macromolecular impurities can be removed through the ultrafiltration membrane, so that the purity of the product is further improved.
The aperture of the ultrafiltration membrane device 18 is 1000-10000Da, the aperture of the ceramic membrane device 5 is 20-100nm, a concentrated solution outlet of the ceramic membrane device 5 is communicated with a ceramic membrane concentrated solution tank 19 through a pipeline, and a concentrated solution outlet of the ultrafiltration membrane device 18 is communicated with an ultrafiltration membrane concentrated solution tank 20 through a pipeline. The ceramic membrane concentrate tank 19 and the ultrafiltration membrane concentrate tank 20 are subjected to environment-friendly pollution discharge treatment, and the amount of generated waste liquid is small and environment-friendly.
The clear liquid outlet of the ultrafiltration membrane apparatus 18 is communicated with a cation exchange resin column 21 through a pipeline, and the outlet of the cation exchange resin column 21 is communicated with the anion exchange resin column 9 through a pipeline. Desalting the feed solution by means of cation exchange resin column 21 further improves the purity of the product.
The filter 8 is one of a ceramic membrane filter 8, a centrifugal machine or a plate-and-frame filter, and the plate-and-frame filter is selected in the embodiment, so that the separation effect is good, the purity of the final product is improved, the effect of concentrating feed liquid is achieved, the subsequent concentration time is saved, and the process period is shortened.
The lower inlet of the anion exchange resin column 9 is communicated with a flushing water tank 22 through a pipeline, and the upper outlet of the anion exchange resin column 9 is communicated with the first concentrator 10 through a pipeline. The anion exchange resin column 9 is washed, so that the material liquid stained on the anion exchange resin column 9 is recovered, waste is avoided, and the utilization rate of raw materials and the yield of products are improved.
It is to be understood that these examples are illustrative of the present utility model and are not intended to limit the scope of the present utility model. Furthermore, it should be understood that various changes and modifications can be made by one skilled in the art after reading the teachings of the present utility model, and such equivalents are intended to fall within the scope of the utility model as defined in the appended claims.
Claims (8)
1. An apparatus for producing D-chiro-inositol and glucuronic acid using inositol, characterized in that: the device comprises a first conversion kettle, wherein an inlet of the first conversion kettle is communicated with an inositol solution tank, a first enzyme solution tank and a buffer solution tank through pipelines respectively, an outlet of the first conversion kettle is communicated with a ceramic membrane device through a pipeline, a clear liquid outlet of the ceramic membrane device is communicated with a second conversion kettle through a pipeline, and an inlet of the second conversion kettle is communicated with a second enzyme solution tank through a pipeline; the outlet of the second conversion kettle is communicated with a filter through a pipeline, and the filtrate outlet of the filter is communicated with an anion exchange resin column through a pipeline;
the outlet of the lower effluent of the anion exchange resin column is communicated with a first concentrator through a pipeline, the inlet of the first concentrator is communicated with an ethanol tank through a pipeline, the outlet of the first concentrator is communicated with a first suction filtration tank through a pipeline, and the outlet of the first suction filtration tank is communicated with a D-chiral inositol tank through a pipeline;
The inlet of the anion exchange resin column is communicated with a hydrochloric acid solution tank through a pipeline, the outlet of the anion exchange resin column is communicated with a second concentrator through a pipeline, the outlet of the second concentrator is communicated with a dryer, and the outlet of the dryer is communicated with a glucuronic acid tank through a pipeline.
2. An apparatus for producing D-chiro-inositol and glucuronic acid using inositol according to claim 1, wherein: the filtrate outlet of the filter is communicated with an ultrafiltration membrane device through a pipeline, and the clear liquid outlet of the ultrafiltration membrane device is communicated to the anion exchange resin column through a pipeline.
3. An apparatus for producing D-chiro-inositol and glucuronic acid using inositol according to claim 2, wherein: the concentrated solution outlet of the ceramic membrane device is communicated with a ceramic membrane concentrated solution tank through a pipeline, and the concentrated solution outlet of the ultrafiltration membrane device is communicated with an ultrafiltration membrane concentrated solution tank through a pipeline.
4. An apparatus for producing D-chiro-inositol and glucuronic acid using inositol according to claim 2, wherein: the clear liquid outlet of the ultrafiltration membrane device is communicated with a cation exchange resin column through a pipeline, and the outlet of the cation exchange resin column is communicated to the anion exchange resin column through a pipeline.
5. An apparatus for producing D-chiro-inositol and glucuronic acid using inositol according to claim 2, wherein: the aperture of the ultrafiltration membrane device is 1000-10000Da.
6. An apparatus for producing D-chiro-inositol and glucuronic acid using inositol according to claim 1, wherein: the aperture of the ceramic membrane device is 20-100nm.
7. An apparatus for producing D-chiro-inositol and glucuronic acid using inositol according to claim 1, wherein: the filter is one of a ceramic membrane filter, a centrifuge or a plate-frame filter.
8. An apparatus for producing D-chiro-inositol and glucuronic acid using inositol according to claim 1, wherein: the lower inlet of the anion exchange resin column is communicated with a flushing water tank through a pipeline, and the upper outlet of the anion exchange resin column is communicated to the first concentrator through a pipeline.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202322508203.9U CN220846152U (en) | 2023-09-15 | 2023-09-15 | Device for producing D-chiral inositol and glucuronic acid by utilizing inositol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202322508203.9U CN220846152U (en) | 2023-09-15 | 2023-09-15 | Device for producing D-chiral inositol and glucuronic acid by utilizing inositol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN220846152U true CN220846152U (en) | 2024-04-26 |
Family
ID=90782230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202322508203.9U Active CN220846152U (en) | 2023-09-15 | 2023-09-15 | Device for producing D-chiral inositol and glucuronic acid by utilizing inositol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN220846152U (en) |
-
2023
- 2023-09-15 CN CN202322508203.9U patent/CN220846152U/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2118294B1 (en) | Method of producing xylitol using hydrolysate containing xylose and arabinose prepared from byproduct of tropical fruit biomass | |
| CN101491323B (en) | New production technique of sodium glutamate | |
| CN104529755B (en) | A kind of method being separated α-ketoglutaric acid from conversion fluid | |
| JP6782779B2 (en) | Method for producing ferulic acid from corn bran with high purity and high yield | |
| CN109574802B (en) | Method for separating 1, 3-propylene glycol, acetic acid and butyric acid from fermentation liquor | |
| CN112979482B (en) | High-purity L-valine as well as preparation method and application thereof | |
| CN113337548B (en) | Preparation method of bio-based 1, 3-propylene glycol | |
| CN111039808A (en) | Method for extracting tyrosine from fermentation liquor | |
| CN105566136A (en) | Method for separating and extracting 4-hydroxyisoleucine from fermentation liquor | |
| CN103387593B (en) | A kind of method of coproduction maltonic acid-delta-lactone, seminose and N.F,USP MANNITOL | |
| CN102102115B (en) | Method for preparing calcium gluconate and isomaltooligosaccharide simultaneously with crystalline glucose mother liquor | |
| CN220846152U (en) | Device for producing D-chiral inositol and glucuronic acid by utilizing inositol | |
| CN103804173A (en) | Fermentation organic acid refining method | |
| CN103420826A (en) | Method for extracting succinic acid from fermentation broth | |
| CN114231578B (en) | Method for preparing psicose by double-enzyme method | |
| CN109369731B (en) | Method for removing glucose in xylose production process | |
| CN111850069A (en) | Production and preparation process of trehalose | |
| CN101475970A (en) | Method for producing crystal D-ribose | |
| CN110294726A (en) | The preparation method of ISOASCORBIC ACID potassium | |
| CN113736842B (en) | Method for efficiently preparing tauroursodeoxycholic acid by multiple cells | |
| CN108220351B (en) | Method for preparing L-arginine-alpha-ketoglutaric acid by biological enzyme method | |
| CN112480127A (en) | Novel method for producing mitomycin | |
| CN109705174B (en) | Method for extracting tobramycin | |
| CN1724678A (en) | Method of producing mannitol using starch as raw material | |
| CN220788618U (en) | D-chiro-inositol's apparatus for producing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |